REDWOOD CITY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will speak at two upcoming investor conferences.
• Jefferies Autumn 2015 Global Healthcare Conference - November 18-19, 2015 - London
< OncoMed’s corporate presentation is scheduled to take place at 2:00 pm GMT on November 19, 2015.
• Piper Jaffray 27th Annual Healthcare Conference – December 1-2, 2015 - New York
Paul Hastings will provide a fireside chat on Tuesday, December 1, 2015 at 8:30 a.m. ET
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin-LGR. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). A wholly owned immuno-oncology candidate, GITRL-Fc, and an undisclosed target that is part of OncoMed’s collaboration with Celgene are being advanced toward clinical trials in the 2016-2017 timeframe.
Please see the company’s website at www.oncomed.com for additional information.
Help employers find you! Check out all the jobs and post your resume.
